Mckinley Capital Management LLC Delaware bought a new position in shares of Audentes Therapeutics Inc (NASDAQ:BOLD) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 47,594 shares of the biotechnology company’s stock, valued at approximately $1,333,000. Mckinley Capital Management LLC Delaware owned about 0.17% of Audentes Therapeutics as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in BOLD. SG Americas Securities LLC bought a new stake in shares of Audentes Therapeutics during the third quarter worth $143,000. Nationwide Fund Advisors raised its position in shares of Audentes Therapeutics by 288.9% during the second quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock worth $164,000 after acquiring an additional 6,384 shares during the last quarter. State of Wisconsin Investment Board bought a new stake in shares of Audentes Therapeutics during the second quarter worth $210,000. Rhumbline Advisers bought a new stake in shares of Audentes Therapeutics during the second quarter worth $252,000. Finally, Virtu KCG Holdings LLC bought a new stake in shares of Audentes Therapeutics during the second quarter worth $257,000. Institutional investors own 78.99% of the company’s stock.

In other Audentes Therapeutics news, SVP David Nagler sold 3,750 shares of the business’s stock in a transaction dated Wednesday, September 27th. The stock was sold at an average price of $30.00, for a total value of $112,500.00. Following the completion of the transaction, the senior vice president now directly owns 3,750 shares of the company’s stock, valued at $112,500. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Orbimed Advisors Llc sold 672,000 shares of the business’s stock in a transaction dated Friday, September 29th. The shares were sold at an average price of $28.25, for a total value of $18,984,000.00. The disclosure for this sale can be found here. Insiders sold 758,500 shares of company stock valued at $21,340,610 in the last quarter. 47.30% of the stock is currently owned by corporate insiders.

Shares of Audentes Therapeutics Inc (NASDAQ:BOLD) opened at $28.38 on Friday. Audentes Therapeutics Inc has a fifty-two week low of $13.90 and a fifty-two week high of $33.43.

Audentes Therapeutics (NASDAQ:BOLD) last released its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.88) EPS for the quarter, meeting analysts’ consensus estimates of ($0.88). sell-side analysts forecast that Audentes Therapeutics Inc will post -3.52 EPS for the current fiscal year.

A number of research firms recently commented on BOLD. Zacks Investment Research downgraded Audentes Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, August 8th. Evercore ISI began coverage on Audentes Therapeutics in a report on Wednesday, August 16th. They issued an “outperform” rating and a $23.00 price objective for the company. ValuEngine downgraded Audentes Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, October 13th. William Blair began coverage on Audentes Therapeutics in a report on Tuesday, October 17th. They issued an “outperform” rating and a $35.00 price objective for the company. Finally, Raymond James Financial began coverage on Audentes Therapeutics in a report on Thursday, October 12th. They issued a “market perform” rating for the company. Two analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $27.17.

ILLEGAL ACTIVITY WARNING: This news story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/02/mckinley-capital-management-llc-delaware-invests-1-33-million-in-audentes-therapeutics-inc-bold.html.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Want to see what other hedge funds are holding BOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Audentes Therapeutics Inc (NASDAQ:BOLD).

Institutional Ownership by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Stock Ratings for Audentes Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc and related stocks with our FREE daily email newsletter.